Yiming Zhong

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 783 citations · Full text

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Rosa Lapalombella, Qingxiang Sun, Katie Williams et al. · Blood · 2012 · 293 citations · Full text

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Jennifer A. Woyach, Kelly A. Smucker, Lisa L. Smith et al. · Blood · 2014 · 273 citations · Full text

Enhancing Mechanical Properties of Silk Fibroin Hydrogel through Restricting the Growth of β-Sheet Domains

Dihan Su, Yao Meng, Jie Liu et al. · ACS Applied Materials & Interfaces · 2017 · 248 citations

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Jason A. Dubovsky, Ryan Flynn, Jing Du et al. · Journal of Clinical Investigation · 2014 · 198 citations · Full text